CD169+ Mφs that infiltrate brain tumors originate from blood monocytes, lymph nodes, the liver, and the spleen; these cells possess the capacity to enhance anti-tumor immune responses through their interaction with red blood cells [55]. This evidence concerns the gene SIGLEC1 and neoplasm.